Epidermal growth factor receptor antagonists in pancreatic cancer: What is their role?

American Journal of Cancer

Volumn 5, Issue 4, 2006, Pages 213-221

  Tang, Patricia A ^a,b   Moore, Malcolm J ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

6 [4 (4 ETHYL 1 PIPERAZINYLMETHYL)PHENYL] 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; BEVACIZUMAB; CANERTINIB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; IRINOTECAN; LAPATINIB; MATUZUMAB; MONOCLONAL ANTIBODY; NIMOTUZUMAB; PACLITAXEL; PANITUMUMAB; PAZOPANIB; UNCLASSIFIED DRUG; XL 647;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DEHYDRATION; DIARRHEA; DOWN REGULATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG ERUPTION; HUMAN; MONOTHERAPY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; RASH; RECEPTOR BLOCKING; RECOMMENDED DRUG DOSE; REVIEW; SURVIVAL TIME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 33846891582     PISSN: 11756357     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024669-200605040-00002     Document Type: Review

References (99)

1. Canadian cancer statistics 2005. Toronto: Canadian Cancer Society/National Cancer Institute of Canada, 2005
2. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005 Jan-Feb; 55 (1): 10-30
3. Geer RJ, Brennan MF. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993 Jan; 165 (1): 68-72
4. Willett CG, Czito BG, Bendell JC, et al. Locally advanced pancreatic cancer. J Clin Oncol 2005 Jul 10; 23 (20): 4538-44
5. Reis LAG, Eisner MP, Kosary CL, et al. SEER cancer statistics review 1975-2003 [online]. Available from URL: http://www.seer.cancer.gov/csr/ 1975_2003/ [Accessed 2005 Nov 4]
6. Burris III HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997 Jun; 15 (6): 2403-13
7. Berlin JD, Catalano P, Thomas JP, et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 2002 Aug 1; 20 (15): 3270-5
8. Bramhall SR, Schulz J, Neuraxitis J, et al. A double-blind placebo-controlled, randomized study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 2002 Jul 15; 87 (2): 161-7
9. Heinemann V, Quietist D, Gisele F, et al. Gemcitabine plus cisplatin versus gemcitabine in advanced pancreatic cancer: preliminary results of a randomized phase III trial [abstract]. J Clin Oncol 2003; 21: 1003
10. Herrmann R, Bodoky G, Ruhstaller T, et al. Gemcitabine plus capecitabine versus gemcitabine alone in locally advanced or metastatic pancreatic cancer: a randomized phase III study of the Swiss Group for Clinical Cancer Research (SAKK) and the Central European Cooperative Oncology Group (CECOG) [abstract]. J Clin Oncol 2005; 23: 4010
11. Louvet C, Labianca R, Hammel P, et al. GemOx (gemcitabine + oxaliplatin) versus Gem (gemcitabine) in non resectable pancreatic adenocarcinoma: final results of the GERCOR/GISCAD Intergroup Phase III [abstract]. J Clin Oncol 2004; 22: 4008
12. O'Reilly EMO, Abou-Alfa GK, Letourneau WG, et al. A randomized phase III trial of DX-8951f (exatecan mesylate; DX) and gemcitabine (GEM) vs. gemcitabine alone in advanced pancreatic cancer (APC) [abstract]. J Clin Oncol 2004; 22: 4006
13. Richards D, Kindler H, Oettle H, et al. A randomized phase III study comparing gemcitabine + pemetrexed versus gemcitabine in patients with locally advanced and metastatic pancreas cancer [abstract]. J Clin Oncol 2004; 22: 4007
14. Riess H, Helm A, Niedergethmann M, et al. A randomised, prospective, multicenter, phase III trial of gemcitabine, 5-fluorouracil (5-FU), folinic acid vs. gemcitabine alone in patients with advanced pancreatic cancer [abstract]. J Clin Oncol 2005; 23: 4009
15. Rocha Lima CM, Green MR, Rotche R, et al. Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 2004 Sep 15; 22 (18): 3776-83
16. Stathopoulos G, Aravantinos G, Syrigos K, et al. A randomized phase III study of irinotecan/gemcitabine combination versus gemcitabine in patients with advanced/metastatic pancreatic cancer [abstract]. J Clin Oncol 2005; 23: 4105
17. Van Cutsem E, van de Velde H, Karasek P, et al. Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 2004 Apr 15; 22 (8): 1430-8
18. Burris III HA, Rivkin S, Reynolds R, et al. Phase II trial of oral rubitecan in previously treated pancreatic cancer patients. Oncologist 2005 Mar; 10 (3): 183-90
19. Cantore M, Rabbi C, Fiorentini G, et al. Combined irinotecan and oxaliplatin in patients with advanced pre-treated pancreatic cancer. Oncology 2004; 67 (2): 93-7
20. Reni M, Panucci MG, Passoni P, et al. Salvage chemotherapy with mitomycin, docetaxel, and irinotecan (MDI regimen) in metastatic pancreatic adenocarcinoma: a phase I and II trial. Cancer Invest 2004; 22 (5): 688-96
21. Ulrich-Pur H, Raderer M, Verena Kornek G, et al. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma. Br J Cancer 2003 Apr 22; 88 (8): 1180-4
22. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000 Oct 13; 103 (2): 211-25
23. Prenzel N, Fischer OM, Streit S, et al. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 2001 Mar; 8 (1): 11-31
24. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990 Apr 20; 61 (2): 203-12
25. Xiong HQ, Abbruzzese JL. Epidermal growth factor receptor-targeted therapy for pancreatic cancer. Semin Oncol 2002 Oct; 29 (5 Suppl. 14): 31-7
26. Dong M, Nio Y, Guo KJ, et al. Epidermal growth factor and its receptor as prognostic indicators in Chinese patients with pancreatic cancer. Anticancer Res 1998 Nov-Dec; 18 (6B): 4613-9
27. Tobita K, Kijima H, Dowaki S, et al. Epidermal growth factor receptor expression in human pancreatic cancer: significance for liver metastasis. Int J Mol Med 2003 Mar; 11 (3): 305-9
28. Ueda S, Ogata S, Tsuda H, et al. The correlation between cytoplasmic overexpresand sion of epidermal growth factor receptor and tumor aggressiveness: poor prognosis in patients with pancreatic ductal adenocarcinoma. Pancreas 2004 Jul; 29 (1): e1-8
29. Yamanaka Y, Friess H, Kobrin MS, et al. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. Anticancer Res 1993 May-Jun; 13 (3): 565-9
30. Akagi M, Kawaguchi M, Liu W, et al. Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells. Br J Cancer 2003 Mar 10; 88 (5): 796-802
31. Goldman CK, Kim J, Wong WL, et al. Epidermal growth factor stimulates vascular endothelial growth factor production by human malignant glioma cells: a model of glioblastoma multiforme pathophysiology. Mol Biol Cell 1993 Jan; 4 (1): 121-33
32. Perrotte P, Matsumoto T, Inoue K, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999 Feb; 5 (2): 257-65
33. Schreiber AB, Winkler ME, Derynck R. Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science 1986 Jun 6; 232 (4755): 1250-3
34. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003 Jul 15; 21 (14): 2787-99
35. Baselga J, Arteaga CL. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer. J Clin Oncol 2005 Apr 10; 23 (11): 2445-59
36. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004 Jul 22; 351 (4): 337-45
37. Lenz H, Mayer RJ, Gold PJ, et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin [abstract]. J Clin Oncol 2004; 22 (14S): 3510
38. Saltz LB, Meropol NJ, Loehrer Sr PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004 Apr 1; 22 (7): 1201-8
39. Saltz LB, Rubin M, Hochster H, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer that expresses the epidermal growth factor receptor [abstract]. J Clin Oncol 2001; 19: 7
40. Bangard C, Gossmann A, Papyan A, et al. Magnetic resonance imaging in an orthotopic rat model: blockade of epidermal growth factor receptor with EMD72000 inhibits human pancreatic carcinoma growth. Int J Cancer 2005 Mar 10; 114 (1): 131-8
41. Bruns CJ, Harbison MT, Davis DW, et al. Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms. Clin Cancer Res 2000 May; 6 (5): 1936-48
42. Bush T, Freeman D, Ogbagabriel S, et al. Antitumor efficacy of panitumumab alone or in combination with chemotherapy against human pancreatic carcinoma xenografts [abstract no. B72]. Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2005 Nov 14-18; Philadephia (PA). Philadephia (PA): American Association of Cancer Research Publications, 2005: 143-4
43. Overholser JP, Prewett MC, Hooper AT, et al. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 2000 Jul 1; 89 (1): 74-82
44. Durkin AJ, Bloomston PM, Rosemurgy AS, et al. Defining the role of the epidermal growth factor receptor in pancreatic cancer grown in vitro. Am J Surg 2003 Nov; 186 (5): 431-6
45. Li J, Kleeff J, Giese N, et al. Gefitinib ('Iressa', ZD1839), a selective epidermal growth factor receptor tyrosine kinase inhibitor, inhibits pancreatic cancer cell growth, invasion, and colony formation. Int J Oncol 2004 Jul; 25 (1): 203-10
46. Ng SS, Tsao MS, Nicklee T, et al. Effects of the epidermal growth factor receptor inhibitor OSI-774, Tarceva, on downstream signaling pathways and apoptosis in human pancreatic adenocarcinoma. Mol Cancer Ther 2002 Aug; 1 (10): 777-83
47. Schmidt-Ullrich RK, Valerie K, Fogleman PB, et al. Radiation-induced autophosphorylation of epidermal growth factor receptor in human malignant mammary and squamous epithelial cells. Radiat Res 1996 Jan; 145 (1): 81-5
48. Akimoto T, Hunter NR, Buchmiller L, et al. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res 1999 Oct; 5 (10): 2884-90
49. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 2002 Dec 15; 62 (24): 7350-6
50. Chua DT, Nicholls JM, Sham JS, et al. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2004 May 1; 59 (1): 11-20
51. Pillai MR, Jayaprakash PG, Nair MK. Tumour-proliferative fraction and growth factor expression as markers of tumour response to radiotherapy in cancer of the uterine cervix. J Cancer Res Clin Oncol 1998; 124 (8): 456-61
52. Krause M, Schutze C, Petersen C, et al. Different classes of EGFR inhibitors may have different potential to improve local tumour control after fractionated irradiation: a study on C225 in FaDu hSCC. Radiother Oncol 2005 Feb; 74 (2): 109-15
53. Nasu S, Ang KK, Fan Z, et al. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys 2001 Oct 1; 51 (2): 474-7
54. Buchsbaum DJ, Bonner JA, Grizzle WE, et al. Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys 2002 Nov 15; 54 (4): 1180-93
55. Chinnaiyan P, Huang S, Vallabhaneni G, et al. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 2005 Apr 15; 65 (8): 3328-35
56. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354 (6): 567-78
57. Iannitti D, Dipetrillo T, Akerman P, et al. Erlotinib and chemoradiation followed by maintenance erlotinib for locally advanced pancreatic cancer: a phase I study. Am J Clin Oncol 2005 Dec; 28 (6): 570-5
58. Kortmansky JS, O'Reilly EMO, Minsky BD, et al. A phase I trial of erlotinib, gemcitabine and radiation for patients with locally-advanced, unresectable pancreatic cancer [abstract]. J Clin Oncol 2005; 23 (16S): 4107
59. Graeven U, Vogel E, Killing B, et al. Phase I study of humanized IgG1 anti-epidermal growth factor receptor monoclonal antibody EMD 72000 plus gemcitabine in advanced pancreatic cancer [abstract]. J Clin Oncol 2004; 22 (14S): 3061
60. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol 2004 Jul 1; 22 (13): 2610-6
61. Saltz LB, Lenz H, Hochster H, et al. Randomized Phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer [abstract]. J Clin Oncol 2005; 23: 3508
62. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005 Aug 20; 23 (24): 5568-77
63. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005 Aug 20; 23 (24): 5578-87
64. Chan AT, Hsu MM, Goh BC, et al. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma. J Clin Oncol 2005 May 20; 23 (15): 3568-76
65. Bandyopadhyay D, Mandal M, Adam L, et al. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem 1998 Jan 16; 273 (3): 1568-73
66. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000 Jun; 6 (6): 2166-74
67. Meyers MB, Merluzzi VJ, Spengler BA, et al. Epidermal growth factor receptor is increased in multidrug-resistant Chinese hamster and mouse tumor cells. Proc Natl Acad Sci U S A 1986 Aug; 83 (15): 5521-5
68. Meyers MB, Yu P, Mendelsohn J. Crosstalk between epidermal growth factor receptor and P-glycoprotein in actinomycin D-resistant Chinese hamster lung cells. Biochem Pharmacol 1993 Nov 17; 46 (10): 1841-8
69. Naruse I, Ohmori T, Ao Y, et al. Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo. Int J Cancer 2002 Mar 10; 98 (2): 310-5
70. Sclabas GM, Fujioka S, Schmidt C, et al. Restoring apoptosis in pancreatic cancer cells by targeting the nuclear factor-kappaB signaling pathway with the anti-epidermal growth factor antibody IMC-C225. J Gastrointest Surg 2003 Jan; 7 (1): 37-43
71. Vergote IB, Humblet Y, Van Cutsem E, et al. A multicenter phase II trial of gefitinib 500 mg/day in 193 patients with advanced epidermal growth factor receptor positive solid tumors who failed previous chemotherapy: interim data [abstract]. J Clin Oncol 2005; 23 (16S): 3162
72. Carneiro B, Brand R, Fine E, et al. Phase I trial of fixed dose rate infusion (FDRI) gemcitabine with gefitinib in patients with advanced pancreatic carcinoma [abstract]. J Clin Oncol 2005; 23 (16S): 4118
73. Blaszkowsky LS, Kulke KH, Ryan DP, et al. A phase II study of erlotinib in combination with capecitabine in previously treated patients with metastatic pancreatic cancer [abstract]. J Clin Oncol 2005; 23 (16S): 4099
74. Moore MJ, Goldstein D, Figer A, et al. Erlotinib plus gemcitabine compared to gemicitabine alone in patients with advanced pancreatic cancer [abstract]. J Clin Oncol 2005; 23: 1
75. Cunningham D, Chau I, Stocken D, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer [abstract no. PS11]. Eur J Cancer 2005; Suppl. 3 (4): 4
76. Perez-Soler R, Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining? J Clin Oncol 2005 Aug 1; 23 (22): 5235-46
77. Clark G, Perez-Soler R, Siu LL, et al. Rash severity is predictive of increased survival with erlotinib HCl [abstract]. J Clin Oncol 2003; 22: 786
78. Saltz L, Kies MS, Abbruzzese JL, et al. The presence and intensity of the cetuximab-induced rash predicts increased survival in studies across multiple malignancies [abstract]. J Clin Oncol 2003; 22: 817
79. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000 Feb; 18 (4): 904-14
80. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002 Nov 1; 20 (21): 4292-302
81. Herbst RS, Maddox AM, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002 Sep 15; 20 (18): 3815-25
82. Hidalgo M, Siu LL, Nemunaitis J, et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 2001 Jul 1; 19 (13): 3267-79
83. Nakagawa K, Tamura T, Negoro S, et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib ('Iressa', ZD1839) in Japanese patients with solid malignant tumors. Ann Oncol 2003 Jun; 14 (6): 922-30
84. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002 May 1; 20 (9): 2240-50
85. Figlin RA, Belldegrum AS, Crawford J, et al. ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody (MAb) in patients with advanced cancer: phase 1 clinical results [abstract]. J Clin Oncol 2002; 21 (10a): 35
86. Rokos L, Lohner M, Osborn K, et al. Low pharmacokinetic variability facilitates optimal dosing of ABX-EGF in cancer patients [abstract]. J Clin Oncol 2002; 21 (91a): 362
87. Chen EX, Zhang W, Pond GR, et al. Correlation between erlotinib concentrations and severity of skin rash. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2005 Nov 14-18; Philadephia (PA). Philadelphia (PA): American Association for Cancer Research Publications, 2005
88. Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005 May 4; 97 (9): 643-55
89. Hirsch FR, Varella-Garcia M, McCoy J, et al. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 2005 Oct 1; 23 (28): 6838-45
90. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004 May 20; 350 (21): 2129-39
91. Takano T, Ohe Y, Sakamoto H, et al. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005 Oct 1; 23 (28): 6829-37
92. Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 2005 Jul 14; 353 (2): 133-44
93. Sihto H, Puputti M, Pulli L, et al. Epidermal growth factor receptor domain II, IV, and kinase domain mutations in human solid tumors. J Mol Med 2005 Dec; 83 (12): 976-83. Epub 2005 Aug 31
94. Rosetti M, Tesei A, Ulivi P, et al. Modulation of drug cytotoxicity by Iressa (ZD1839) in pancreatic cancer cell lines. Cancer Biol Ther 2005 Oct 7; 4 (10): 1089-95
95. Thomson S, Buck E, Petti F, et al. Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition. Cancer Res 2005 Oct 15; 65 (20): 9455-62
96. Buck A, Eyzaguirre A, Gibson N, et al. Identification of E-cadherin and HER3 as biomarkers for sensitivity to the EGFR kinase inhibitor erlotinib in pancreatic and colorectal cancers [abstract no. B66]. Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2005 Nov 14-18; Philadephia (PA). Philadephia (PA): American Association for Cancer Research Publications, 2005: 142
97. Huang S, Armstrong EA, Benavente S, et al. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor. Cancer Res 2004 Aug 1; 64 (15): 5355-62
98. Matar P, Rojo F, Cassia R, et al. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting. Clin Cancer Res 2004 Oct 1; 10 (19): 6487-501
99. Tabernero J, Schffski P, Rojo F, et al. Combined anti-EGFR blockade: a phase I pharmacokinetic and molecular pharmacodynamic study of cetuximab (Erbitux) and gefitinib (Iressa) in patients with advanced colorectal, head and neck, and non-small cell lung cancer expressing the EGFR [abstract no. A107]. Proceedings of the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; 2005 Nov 14-18; Philadephia (PA). Philadephia (PA): American Association for Cancer Research Publications, 2005: 82